Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomes

NASHUA, N.H., May 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its Breast AI Suite is a winner of the U.S. General Services Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competiti... Continue reading

Company to host conference call and webcast today at 4:30 PM ET 

NASHUA, N.H. – May 15, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. 

Highlights:

98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published in Journal of Contemporary Brachytherapy

NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer (NMSC). In the longest-term study of Xof... Continue reading

iCAD’s AI solution minimizes interval cancers and overcomes challenges associated with digital breast tomosynthesis

NASHUA, N.H., May 3, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world’s largest breast imaging conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7 in National Harbor, MD. Attendees are i... Continue reading

NASHUA, N.H., May 1, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, May 15, 2023.

Earnings call details are as follows:

Domestic: 877-545-0523

International: 973-528-0016

Continue reading

Kathy Schilling, MD, Boca Raton Regional Hospital, to discuss how ProFound AI helped nine dedicated breast radiologists find 23% more cancers, without increasing the rate of recalls

NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital. The live event,... Continue reading

New research presented at American Roentgen Ray Society (ARRS) meeting continues to validate unique value iCAD’s deep-learning breast AI solution offers to clinicians and patients

NASHUA, N.H., April 20, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies. One... Continue reading

Eric Lonnqvist as Chief Financial Officer, Vasu Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations Officer bolster the Company’s executive leadership team and accelerate the Company’s growth strategies

NASHUA, N.H., April 17, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Pro... Continue reading

ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer

NASHUA, N.H., April 4, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new clinical evidence published in the Journalof Clinical Oncology found ProFound AI® Risk for 2D Mammography is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model, for both short-term... Continue reading

     Strategy focused on profitability by end of 2024, using current cash on hand

New leadership to host conference call and webcast today at 4:30 PM ET

NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022.

Highlig... Continue reading

iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference 

NASHUA, N.H., March 23, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its technologies are empowering customers to lead the way in breast care, while supporting the national breast density reporting standard recently established by the U.S. Food and Drug Administration (FDA). The Company will be showcasing its Breast AI Suite... Continue reading

Company is exploring strategic options for its Therapy business line

NASHUA, N.H., March 13, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023.

Based on preliminary, unaudited financial infor... Continue reading

Stacey Stevens Resigns as President and CEO and as a Member of the Board

Dana Brown Named President and CEO, remains Chairman of the Board

NASHUA, N.H. – March 13, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has accepted the resignation, for personal reasons, of Stacey Stevens as President and CEO. Stacey will remain with the Company through Apr... Continue reading

Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023

NASHUA, N.H. – March 1, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world clinical evidence to be presented at the European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts radiologists’ efficiency and accuracy. The Company is also showcasing its Breast AI Suite of deep... Continue reading

NASHUA, N.H., February 9, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023 in Snowbird, UT.

Stacey Stevens, President and CEO of iCAD, Inc., will participate in one-on-one meetings with investors at the event. Please contact your BTIG representative for further information or to request a meeting.

Continue reading

Daniel Shea appointed as interim Chief Financial Officer

William Keyes hired as Senior Vice President, US Commercial Sales, AI

NASHUA, N.H. – January 23, 2023 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Daniel Shea, CPA, as interim Chief Financial Officer (CFO), effective immediately. The Company has launched a search for a full-time CFO, with the goal... Continue reading

Dana Brown named Executive Chair of the Board  

NASHUA, N.H. – January 11, 2023 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors. Ms. Brown has been a non-executive board member since February 2022. Prior to joining iCAD’s board, Ms. Brown was the Senior Vice President, Chief Strategy and Operations Officer for... Continue reading

Solis Mammography’s Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of ProFound AI

NASHUA, N.H. – December 5, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Solis Mammography, the largest independent provider of breast screening and diagnostic services in the United States, will be featured in the next “ProFound Insights, ProFound Impact” webinar, on Dec. 14 at 3 pm EST / 12 pm P... Continue reading

Google Health AI and Cloud technology to be integrated into iCAD’s portfolio with potential to elevate performance and expand access to millions of women worldwide

Agreement marks Google Health’s first partnership with a mammography AI vendor

NASHUA, N.H. – November 28, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a strategic development... Continue reading

Study affirms utility of ProFound AI’s Case Scores in improving cancer detection

Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at largest medical imaging forum in the world

NASHUA, N.H. – November 21, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new and real-world research demonstrating the value of its Breast AI Suit... Continue reading